Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)

Anika Therapeutics (ANIK) has disclosed Liabilities from Discontinued Operations for 2 consecutive years, with 4122000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Liabilities from Discontinued Operations rose 316.78% to 4122000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 4122000.0, a 316.78% increase, with the full-year FY2024 number at 4122000.0, up 316.78% from a year prior.
  • Liabilities from Discontinued Operations was 4122000.0 for Q4 2024 at Anika Therapeutics, up from 989000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 4122000.0 in Q4 2024 to a low of 989000.0 in Q4 2023.